An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-infected subjects

Trial Profile

An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-infected subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2013

At a glance

  • Drugs Abacavir; Lamivudine/abacavir; Lamivudine/zidovudine/abacavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
    • 10 Aug 2007 Status changed from in progress to completed.
    • 12 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top